<DOC>
	<DOCNO>NCT00474669</DOCNO>
	<brief_summary>The primary objective ass maximum tolerate dose docetaxel administer intraperitoneally heat time second-look surgery patient stage II/III ovarian carcinoma .</brief_summary>
	<brief_title>A Phase I Study Intraperitoneal Hyperthermic Docetaxel</brief_title>
	<detailed_description>This phase I study intraperitoneal hyperthermic docetaxel give time second look surgery follow front-line normothermic intraperitoneal intravenous cisplatin/paclitaxel patient stage II III ovarian carcinoma . The primary objective assess maximum tolerate dose docetaxel administer intraperitoneally heat time assess toxicity morbidity associate treatment . Eligible patient complete clinical response front-line therapy .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Patients must complete clinical response ( negative clinical examination , CA125 CT scan chest , abdomen pelvis ) frontline therapy stage II/III ovarian , primary peritoneal Fallopian tube carcinoma . This include initial surgery follow combined IV/IP chemotherapy cisplatin paclitaxel . Patients must minimum three course IP therapy paclitaxel cisplatin Second surgery perform 3 month last course initial chemotherapy Age great 18 year negative pregnancy childbearing potential GOG performance status le 2 Medically fit surgery Patients must normal organ marrow function define protocol hepatic function Total Bilirubin ULN AST ALT Alkaline Phosphatase must within range allow eligibility . In determine eligibility abnormal two value AST ALT ) use . Ability understand willingness sign write informed consent document . The effect docetaxel develop human fetus unknown . For reason taxanes know teratogenic , woman childbearing potential must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Patients complete frontline therapy ovarian cancer 3 month prior HIPEC . Patients receive investigational agent . Patients stage IV disease include previous parenchymal liver disease , brain metastasis cytologicallyconfirmed chest metastasis Patients history severe hypersensitivity reaction TaxotereÂ® drug formulate polysorbate 80 . History allergic reaction attribute compound similar chemical biologic composition use study addition Taxotere . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . More grade 2 peripheral neuropathy prior chemotherapy Pregnant , breastfeed know HIV positive Prior malignancy nonmelanomatous skin cancer 5 year ago No prior chemotherapy frontline ovarian cancer radiation reason . Stomatitis grade Uncontrolled intercurrent illness condition would limit compliance study requirement exclude .</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Ovarian Carcinoma</keyword>
</DOC>